

PC9674AJTJ

SOLID PHARMACEUTICAL DISPERSIONS WITH ENHANCED BIOAVAILABILITY

Field of the Invention

5 This invention relates to compositions of drugs that have increased aqueous concentration, to processes for preparing such compositions, and to methods of using such compositions. In particular, it relates to compositions comprising a spray dried dispersion of a sparingly soluble drug in hydroxypropylmethylcellulose acetate succinate.

10

Background of the Invention

 It is known in the pharmaceutical arts that low-solubility drugs often show poor bioavailability or irregular absorption, the degree of irregularity being affected by factors such as dose level, fed state of the patient, and form of the drug.

15 Solid dispersions of a drug in a matrix can be prepared by forming a homogeneous solution or melt of the drug and matrix material followed by solidifying the mixture by cooling or removal of solvent. Such dispersions have been known for more than two decades. Such solid dispersions of crystalline drugs often show enhanced bioavailability when administered orally relative to oral compositions
20 comprising undispersed crystalline drug.

 In general, it is known that the use of water-soluble polymers as the matrix material generally yields good results. Examples of water soluble polymers which have been employed include polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), methyl cellulose (MC), block
25 copolymers of ethylene oxide and propylene oxide (PEO/PPO), and polyethyleneglycol (PEG). In a 1986 review of solid amorphous dispersions, see Ford, J.L., Pharm Acta. Helv., 61:3 (1986), criteria are set forth for choosing a suitable matrix, termed a "carrier" therein. The first and most important criterion listed therein is that the carrier "should be freely water soluble with intrinsic rapid dissolution
30 properties." As a result of this view, which is currently widely held, the majority of reports of solid amorphous dispersions of drugs in polymers use polymers which rapidly dissolve in water or gastric fluid such as PVP, PEG, or other water-soluble polymers.

EXPRESS MAIL NO. EL 70931986405

There have been a relatively small number of reports of using water insoluble polymers as the matrix material for solid amorphous dispersions, although in some cases such polymers are soluble in aqueous base. The clear focus of most of these reports is on achieving sustained release of the drug, as opposed to increasing bioavailability. For example, sodium carboxymethylcellulose (NaCMC) and hydroxypropylmethyl cellulose acetate succinate (HPMCAS), both polymers that are insoluble in water or gastric fluid but soluble in aqueous base, such as solutions containing sufficient base to have a pH of 6.5 or greater following dissolution of HPMCAS, have been used in an attempt to simultaneously encapsulate and form a dispersion of drug via a spray-drying process. See Wan et al., Drug Development and Industrial Pharmacy, 18:9, 997-1011 (1992). The authors attempted to form a dispersion of theophylline in HPMCAS by dispersing crystals of theophylline and particles of HPMCAS in water. Neither the drug nor the HPMCAS dissolved appreciably in the water. The resulting slurry was spray dried and resulted in a product (p.1009, line 11) consisting of long thin needle-like theophylline with scattered HPMCAS particles. The authors concluded (p.1010, line 5) that of the polymers studied, only HPMCAS was found unsuitable for their process. The authors state that the intent of the process was to retard rather than enhance the rate of release of drug. Indeed, for all polymers disclosed, *in vitro* tests showed drug concentrations that were the same or lower than that obtained with drug alone.

Miyajima et al., US Patent No. 4,983,593, disclose, *inter alia*, formulating HPMCAS with a drug designated as NZ-105. The patent disclosed that there is formed "a composition having a remarkably enhanced bioavailability and easily prepared into tablets, capsules, granules, powders, and the like..." The patent teaches that the formulations can be prepared by dissolving NZ-105 and HPMCAS in an organic solvent and removing the solvent by means of vacuum-drying, spray-drying, freeze-drying, or the like, or by coating a filler such as an inorganic salt (e.g., calcium hydrogen phosphate) or a sugar (e.g., lactose, sucrose, and so forth) and the like by means of a fluidized bed granulation method, a centrifugal coating method, or a pan coating method to produce granules. The patent discloses that granules can also be prepared by adding a solvent to a filler and kneading the mixture followed by drying. All examples in the patent describe forming a dispersion of HPMCAS and NZ-105 by either (1) fluidized bed granulation by coating either

calcium hydrogen phosphate particles or lactose crystals to form large particles up to 1400 μm in diameter or 2) vacuum drying with lactose to form a solid cake that is then pulverized to form a powdery material.

Nakamichi et al., US Patent No. 5,456,923, disclose, inter alia, a process for
5 producing solid dispersions by passing a mixture of a drug and a polymer carrier through a twin screw compounding extruder. HPMCAS is mentioned as one polymer from among a group of suitable polymers which can be used.

U. S. Patent No. 5,456,923 to Shogo et al discloses an extrusion method for making solid dispersions. HPMCAS is included in a list of polymeric materials,
10 including materials such as starch or gelatin, that can be used as matrix materials.

Takeichi et al, Chem. Pharm. Bull, 38 (9), 2547-2551 (1990) attempted to use a solid dispersion of HPMCAS and uracil made by grinding in a ball mill to enhance rectal absorption, but concluded that uracil absorption was lower than for low molecular weight matrix materials such as sodium caprate. The use of
15 HPMCAS was not recommended.

Baba, et al, Chem. Pharm. Bull, 38 (9), 2542-2546 (1990) made ground mixtures of uracil and HPMCAS along with 50 other matrix materials. Although some enhancement (about a factor of 2) in the dissolution of uracil was observed in the co-ground HPMCAS material relative to a simple mixture of crystalline drug and
20 HPMCAS, the enhancement decreased as the polymer-to-drug ratio was increased. This led the researchers to conclude that HPMCAS adsorbed on the surface of the uracil thereby hindering the dissolution of uracil. Its use was not recommended.

T. Yamaguchi et al, Yakuzaigaku, 53 (4), 221-228 (1993) prepared solid amorphous dispersions of 4"-0-(4-methoxyphenyl)acetyltylosin (MAT) in HPMCAS
25 as well as CMEC. Dissolution tests at pH 4.0 showed supersaturated concentrations of MAT 9-fold that of crystalline MAT with HPMCAS dispersions. This concentration was comparable to that obtained with the dissolution of amorphous drug alone. However, the presence of HPMCAS sustained the supersaturation longer than the amorphous drug alone. The authors report that even better results were obtained
30 with the CMEC dispersions, however, causing the authors to conclude that CMEC is the preferred dispersion matrix.

Summary of the Invention

In a first aspect, this invention provides a composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS), said dispersion
5 providing a maximum concentration of said drug in a use environment that is higher by a factor of at least 1.5 relative to a control composition comprising an equivalent quantity of undispersed drug.

In another aspect, this invention provides a method of increasing the bioavailability of a sparingly-soluble drug, comprising administering said drug in a
10 composition comprising a spray dried solid dispersion, which dispersion comprises said drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS), said dispersion providing a concentration of said drug in a use environment that is higher by a factor of at least 1.5 relative to a composition comprising an equivalent quantity of undispersed drug.

15 In another aspect this invention provides a process for making a spray dried solid dispersion comprising

A. forming a solution comprising (i) HPMCAS, (ii) a sparingly water-soluble drug, and (iii) a solvent in which both (i) and (ii) are soluble; and

B. spray drying said solution, thereby forming spray dried particles having an
20 average diameter less than 100 μm . In a preferred embodiment the concentration of drug in the solvent is less than 20g/100g of solvent with a total solids content less than 25 weight %, preferably less than 15 weight %. In another preferred embodiment the spray drying is conducted under conditions whereby the droplets solidify in less than 20 seconds.

25 The sparingly soluble drugs suitable for use in this invention can be crystalline or amorphous in their undispersed state. A crystalline drug, once dispersed, is substantially non-crystalline as determined by scanning calorimetry or x-ray diffraction.

The term "drug" in this specification and the appended claims is conventional,
30 denoting a compound having beneficial prophylactic and/or therapeutic properties when administered to an animal, including humans.

A use environment can be either the *in vivo* environment of the gastrointestinal tract of an animal, particularly a human, or the *in vitro* environment of a test solution, an example being "MFD" (for model fasted duodenal) solution. A dispersion (or a composition comprising a dispersion) can correspondingly be tested
5 *in vivo* or, more conveniently, tested *in vitro* as further disclosed and discussed below to ascertain whether it is within the scope of the invention.

In a preferred embodiment the drug/HPMCAS spray dried dispersion itself consists essentially of sparingly soluble drug and HPMCAS. Other components can be included in the dispersion if they are inert in the sense that they do not adversely
10 affect the maximum supersaturated concentration (MSSC) of drug achievable with the dispersion in a use environment. Components which do affect the MSSC can also be included, so long as they do not adversely affect (i.e., by lowering) the MSSC materially, meaning that all such components in the dispersion do not lower the
15 MSSC by more than 20% relative to a spray dried dispersion not containing such components. Components which do not affect, or in fact improve MSSC, can be included in any amount. Generally, the amount of HPMCAS and drug in the dispersion, not counting any residual solvent, should be greater than 75% by weight.

In vitro, a composition of matter comprising a spray-dried dispersion of a sparingly soluble drug in HPMCAS is within the scope of the invention if, when said
20 dispersion is dissolution tested, the maximum supersaturated concentration of said drug achievable with said dispersion is higher by a factor of at least 1.5 relative to the equilibrium concentration achieved by dissolution testing a composition comprising an equivalent quantity of undispersed drug. "Dissolution testing" refers to a
25 repeatable, standardized test which employs, as a test medium, an aqueous liquid in which HPMCAS is soluble. Generally, aqueous liquids (i.e., water solutions) having a pH of 6 and higher following dissolution of HPMCAS are satisfactory. Of course, the test should also be capable of reproducibly evaluating equilibrium and/or
supersaturated concentrations of a drug. A convenient dissolution test employs
30 MFD solution as a test medium in a USP-2 apparatus as described in United States Pharmacopoeia XXIII (USP) Dissolution Test Chapter 711, Apparatus 2. Solution volume, paddle speed and temperature are not considered to be critical so long as test dispersions and controls are tested under like or standardized conditions, for example 500 mL of MFD, paddle speed of 100 rpm, and 37°C. Other values for

these parameters can be employed so long as they are maintained constant such that the concentrations being measured are measured under the same conditions. Dissolution testing is typically conducted by comparing a test composition comprising a drug/HPMCAS dispersion with a control composition identical except that it contains pure drug in its equilibrium -- either crystalline or amorphous --form. The control composition is typically the same as the test composition but for the inclusion of HPMCAS. The HPMCAS can simply be omitted altogether and just the drug added to the remainder of the composition, or the HPMCAS can be replaced by an equal amount of inert, non-adsorbing solid diluent such as microcrystalline cellulose. Thus, the control composition should also contain any excipients and/or other components, in the amounts such other components are contained by the test composition.

Preferred dispersions are those for which the *in vitro* (e.g., MFD) drug concentration falls to no less than 25% of the MSSC during the 15 minutes after MSSC is reached, preferably 30 minutes after MSSC is reached.

In the same manner, a composition of matter comprising a spray-dried dispersion of a sparingly soluble drug in HPMCAS is within the scope of the invention if, when a composition comprising said dispersion is tested *in vivo*, the C_{max} achieved with said composition is higher by a factor of at least 1.25 (i.e., 25% higher) relative to the C_{max} achieved with a composition comprising an equivalent quantity of undispersed drug. As indicated above, C_{max} is an abbreviation for the maximum drug concentration in serum or plasma of the test subject. *In vivo* testing protocols can be designed in a number of ways. By measuring the C_{max} for a population to which the test composition has been administered and comparing it with the C_{max} for the same population to which the control has also been administered, the test composition can be evaluated.

Compositions according to the invention exhibit at least a factor of 1.25 improvement in AUC, which is a determination of the area under a curve (AUC) plotting the serum or plasma concentration of drug along the ordinate (Y-axis) against time along the abscissa (X-axis). Generally, the values for AUC represent a number of values taken from all the subjects in a patient test population and are, therefore, mean values averaged over the entire test population. By measuring the AUC for a population to which the test composition has been administered and

comparing it with the AUC for the same population to which the control has been administered, the test composition can be evaluated. AUC's are well understood, frequently used tools in the pharmaceutical arts and have been extensively described, for example in "Pharmacokinetics Processes and Mathematics", Peter E.

- 5 Welling, ACS Monograph 185; 1986. AUCs for this invention were typically determined over a period of 48 or 72 hours starting from the time the dispersion or control was first administered.

Thus, a composition is within the scope of the invention if it exhibits *in vivo* either a C_{max} or an AUC that is 1.25 times the corresponding C_{max} or AUC
10 exhibited by a composition comprising an equivalent quantity of undispersed drug. In a preferred embodiment, compositions according to the invention, in addition to displaying at least a factor of 1.25 improvement in C_{max} as discussed above, also exhibit at least a factor of 1.25 improvement in AUC.


C_{max} and AUC can be determined in humans or a suitable animal model,
15 such as dogs.

A "sparingly-soluble drug" as employed above applies to drugs which are essentially totally water-insoluble or poorly water-soluble. More specifically, the term applies to any beneficial therapeutic agent which has a dose (mg) to aqueous solubility (mg/ml) ratio greater than 100ml, where the drug solubility is that of the
20 neutral (e.g., free base or free acid) form in unbuffered water. This definition includes but is not limited to drugs that have essentially no aqueous solubility (less than 1.0 µg/ml) since it has been determined that the invention has benefit for such drugs. In general, the drug is dispersed in the HPMCAS such that most of the drug is not present in crystalline form greater than about 0.1 µ in diameter. The drug may
25 be present in amorphous drug-rich domains as long as the drug will dissolve to form supersaturated solutions in *in vitro* tests disclosed hereinafter. However, it is generally preferred for the drug to be molecularly dispersed such that there is little or no drug present as separate amorphous domains.


For the purposes of this invention, a "sparingly soluble amorphous drug" is a
30 drug that, in its amorphous state, is sparingly soluble as described above and also, upon storage for 30 days at 30 °C shows no tendency to crystallize as measured by calorimetric techniques or powder x-ray diffraction. An example of such a drug is N-

tert-butyl-2-{3-[3-(3-chloro-phenyl)-unreido]-8-methyl-2-oxo-5-phenyl-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl}-acetamide, which has an aqueous solubility (pH 6.5) of less than 3.0 µg/ml and a broad melting range of 115° to 137°C.


- A preferred class of compounds for use in this invention is glycogen phosphorylase inhibitors, such as those disclosed in PCT/IB95/00443, published internationally as WO96/39385 on December 12, 1996. Specific compounds include those having the structures



and




Another preferred class of compounds for use in this invention is 5-lipoxygenase inhibitors, such as those disclosed in PCT/JP94/01349, published as WO 95/05360. A preferred compound has the structure




Another preferred class of compounds for use in this invention is corticotropic releasing hormone (CRH) inhibitors such as those disclosed in PCT/IB95/00439 published as WO95/33750. Specific compounds include those having the following

5 structure:



and



Another preferred class of compounds is antipsychotics. A particularly
10 preferred compound is ziprasidone.

Other preferred compounds include griseofulvin, nifedipine, and phenytoin.

The specific compounds and classes disclosed above are understood to include all forms thereof, including pharmaceutically acceptable salts, hydrates, polymorphs, and stereoisomers.

“MFD” is an acronym meaning “model fasted duodenal” fluid which is employed as an *in vitro* test medium for purposes of determining whether a particular drug/HPMCAS dispersion falls within the scope of this invention. The MFD test medium allows testing in more convenient *in vitro* conditions and environment by virtue of mimicking an *in vivo* environment. For purposes of this invention, MFD is water which is 82 mM (millimolar) in NaCl, 20 mM in Na₂HPO₄, 47 mM in KH₂PO₄, 14.7 mM in sodium taurocholate and 2.8 mM in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine to yield a solution pH of about 6.5 and osmotic pressure of about 290 mOsm/kg. MFD is described in greater detail below.

The term “HPMCAS” as used herein refers to a family of cellulose derivatives that can have (1) two types of ether substituents, methyl and/or 2-hydroxypropyl and (2) two types of ester substituents, acetyl and/or succinyl. It is referred to in scientific literature as O-(2-hydroxypropyl)-O-methyl-cellulose acetate succinate. The degree of substitution for each of the four general types just noted can be varied over a wide range to effect the chemical and physical properties of the polymer. This versatility of HPMCAS allows its structure to be optimized to obtain good performance with a particular drug of interest. HPMCAS can be synthesized as noted below or purchased commercially. Three examples of commercially available HPMCAS include Shin-Etsu AQOAT[®]-LF, Shin-Etsu AQOAT[®]-MF, and Shin-Etsu AQOAT[®]-HF. All three of these polymers are manufactured by Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan), and all three have proven to be suitable for use in practicing the present invention. The specific grade that yields the best performance for obtaining and sustaining supersaturation in *in vitro* tests and obtaining high bioavailability *in vivo*, varies depending on the specific chemical and physical properties of the drug to be delivered. A preferred mean weight average molecular weight range for HPMCAS is 10,000 to one million daltons, preferably 10,000 to 400,000 daltons, as determined using polyethylene oxide standards.

Drugs which are preferred for use in this invention include those which have a dose to aqueous solubility greater than 100, where the aqueous solubility is

measured in unbuffered water. For ionizable compounds, the appropriate solubility is that of the free base, free acid, or zwitterion, i.e., the solubility of the neutral form. Drugs which will particularly benefit from formulation in spray-dried HPMCAS dispersions of this invention include those drugs which have a dose to aqueous solubility ratio greater than 500. Examples of such drugs are disclosed in the examples herein.

In general, when "solubility" is referred to, aqueous solubility is intended unless otherwise indicated.

It has been determined that a spray dried solid dispersion of a sparingly-soluble drug in HPMCAS has unique properties making it broadly useful for preparing oral dosage forms. While not wishing to be bound by any particular theory or mechanism, it is believed that in order for a solid amorphous dispersion of a drug in a matrix material to function optimally in improving the bioavailability of sparingly-soluble drugs, the matrix material must generally provide the following functions:

1. disperse the drug, thereby preventing or retarding the rate of crystallization in the solid state,
2. dissolve *in vivo*, thereby allowing the drug to be released to the gastrointestinal tract,
3. inhibit the precipitation or crystallization of aqueous dissolved drug.

It has been determined that a spray-dried solid dispersion of a sparingly soluble drug in HPMCAS is superior insofar as above functions 1-3 are concerned, and that such dispersions provide unexpectedly good formulatability and solubility.

If a drug does not have a strong tendency to crystallize from the amorphous solid state, then only the latter two functions are required. When a solid amorphous dispersion of a drug in HPMCAS is prepared, the drug will, either prior to or following dissolution of the drug HPMCAS dispersion, reach a concentration substantially higher than the equilibrium solubility of the drug alone. That is, the drug reaches a supersaturated concentration, and this supersaturated concentration will be maintained for a relatively long time period. HPMCAS functions well in all three respects noted above such that it is unique among known matrix materials in its ability to inhibit the precipitation or crystallization of a broad range of sparingly soluble drugs from a supersaturated solution. Further, and again without wishing to be bound by theory, it is believed that spray drying effects rapid solvent removal so

that crystallization of drug and HPMCAS is largely prevented, or at least minimized relative to other methods of forming dispersions, including other solvent removal processes such as rotary evaporation. In addition, in many cases spray drying effects removal of solvent sufficiently fast that even phase separation of amorphous drug and HPMCAS is largely prevented or minimized. Thus, HPMCAS and spray drying afford a better, more truly homogeneous dispersion in which the drug is more efficiently dispersed in the polymer. Increased efficiency of dispersion from spray drying gives, relative to other methods of making dispersions, a higher drug concentration in *in vitro* tests.

10 Surprisingly, a solid amorphous dispersion comprising a spray dried mixture of HPMCAS and a sparingly soluble amorphous drug, that is, one that shows little tendency to crystallize from its amorphous state can benefit from this invention. Solid dispersions of such drugs in HPMCAS surprisingly show high degrees and durations of supersaturation in *in vitro* dissolution tests relative to compositions comprising undispersed amorphous drug. This finding runs contrary to conventional wisdom in that attempts to enhance the bioavailability of drugs by making solid amorphous dispersions have been directed exclusively toward drugs that, in their pure state, are crystalline or, if made amorphous, spontaneously progress toward the crystalline state. In fact, in the course of developing an appropriate matrix material, two *in vitro* screening methods (see Examples 2 and 3) have been developed and employed to screen a wide range of drugs. The results of these *in vitro* screening tests, based on drug levels in MFD solution, are predictive of *in vivo* bioavailability based on drug levels in blood when dosed orally to dogs or humans. Results obtained from these screening tests support the surprising finding that amorphous dispersions of hydrophobic drugs that are either amorphous in their pure state or show little tendency to be crystalline (e.g., crystal forces are low) also have greatly improved degrees and durations of supersaturation in *in vitro* dissolution tests relative to amorphous drug alone. This finding is surprising in that conventional wisdom holds that the function of dispersing a drug in a matrix material is to prevent or retard its crystallization, and thus that using such matrices should do little to increase the solubility of a drug which is already non-crystalline.

Brief Description Of The Figures

Figure 1 is a schematic diagram of a mini spray drying apparatus used for the examples.

Figure 2 is a schematic diagram of a micro spray drying apparatus used for the examples.

Detailed Description of the Invention and Preferred Embodiments

Synthesis of HPMCAS can be conducted by treating O-(hydroxypropyl)-O-methylcellulose with acetic anhydride and succinic anhydride, as set forth in Tezuka et al, Carbohydrate Research 222(1991)255-259 and in Onda et al, US Patent No. 4,385,078, the teachings of which are incorporated herein by reference. Although such derivatives of cellulose are often considered in the literature as simply having varying average amounts of the four substituents attached to the three hydroxyl groups on each of the glucose repeat units of cellulose, ¹³C-NMR research suggests that most of the hydroxyl groups initially present on the 2-hydroxypropyl groups are substituted by methyl, acetyl, succinyl, or a second 2-hydroxypropyl group, see US 4,385,078. Although essentially any degree of substitution of the various groups can be used as long as the resulting polymer is soluble at the pH of the small intestine, e.g., pH 6 to 8, the amounts of the substituents methoxy, hydroxypropoxy, acetyl, and succinyl, are generally in the range of 10 to 35 wt%, 3 to 15 wt%, 3 to 20 wt%, and 2 to 30 wt%, respectively. Preferably, the amounts of the substituents are 15 to 30 wt%, 4 to 11 wt%, 4 to 15 wt%, and 3 to 20 wt%, respectively. Alternatively, HPMCAS may easily be purchased from a number of commercial suppliers.

The amount of HPMCAS relative to the amount of drug present in the dispersions of the present invention can vary widely from a drug:polymer weight ratio of 1 to 0.2 to 1 to 100. However, in most cases it is preferred that the drug to polymer ratio is greater than 1 to 0.4 and less than 1 to 20. The minimum drug:polymer ratio that yields satisfactory results varies from drug to drug and is best determined in the *in vitro* dissolution tests described below.

Although the key ingredients present in the solid amorphous compositions of the present invention are simply the drug to be delivered and HPMCAS, the inclusion of other excipients in the dispersion may be useful and even preferred. For example, polymers other than HPMCAS that are soluble in aqueous solutions over at least a

portion of the range pH 1.0 and 8.0 can be included in the dispersion along with HPMCAS. For example, it has been found that amorphous dispersions of drug and conventional matrix materials such as PVP, HPC, or HPMC can be formed and then triturated with HPMCAS and still have, for some drugs, superior performance relative to the same dispersions without HPMCAS. In such cases, it appears that, whether the drug is crystalline or amorphous, HPMCAS may have as its primary benefit inhibition of the precipitation or crystallization of drug from supersaturated solution. Included as a preferred embodiment of this invention are dispersions in which drug, HPMCAS, and one or more additional polymers are co-spray dried, wherein drug and HPMCAS constitute not more than 75% of the dispersion.

Another type of excipient useful as a component of the dispersions herein is a surface-active agent such as a fatty acid and alkyl sulfonate; commercial surfactants such as those sold under tradenames such as benzethonium chloride (Hyamine® 1622, available from Lonza, Inc., Fairlawn, NJ, docusate sodium (available from Mallinckrodt Spec. Chem., St. Louis, MO, and polyoxyethylene sorbitan fatty acid esters (Tween®, available from ICI Americas Inc, Wilmington, DE, Liposorb® P-20, available from Lipochem Inc, Patterson, NJ, and Capmul® POE-0, available from Abitec Corp., Janesville, WI), and natural surfactants such as sodium taurocholic acid, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, lecithin, and other phospholipids and mono- and diglycerides. Such materials can advantageously be employed to increase the rate of dissolution by facilitating wetting, thereby increasing the maximum drug concentration and the degree of supersaturation attained, and also to inhibit crystallization or precipitation of drug by interacting with dissolved drug by mechanisms such as complexation, formation of inclusion complexes, formation of micelles or adsorbing to the surface of solid drug, crystalline or amorphous. These surface active agents may comprise up to 25% of the spray-dried dispersion.

Addition of pH modifiers such as acids, bases, or buffers can also be beneficial. pH modifiers can advantageously serve to retard the dissolution of the dispersion (e.g., acids such as citric acid or succinic acid) or, alternatively, to enhance the rate of dissolution of the dispersion (e.g., bases such as sodium acetate or amines). Addition of conventional matrix materials, surface active agents, fillers,

disintegrants, or binders may be added as part of the dispersion itself, added by granulation via wet or mechanical or other means. When such additives are included as part of the dispersion itself, they can be mixed with drug and HPMCAS in the spray drying solvent, and may or may not dissolve along with the drug and

5 HPMCAS prior to forming the dispersion by spray drying. These materials may comprise up to 25% of the drug/HPMCAS/additive dispersion.

In addition to drug and HPMCAS (and other polymers as discussed immediately above), other conventional formulation excipients can be employed in the compositions of this invention, including those excipients well known in the art.

10 Generally, excipients such as fillers, disintegrating agents, pigments, binders, lubricants, flavorants, and so forth can be used for customary purposes and in typical amounts without affecting the properties of the compositions. These excipients are utilized after the HPMCAS/drug dispersion has been formed, in order to formulate the dispersion into tablets, capsules, suspensions, powders for suspension, creams,

15 transdermal patches, and the like.

The term spray-drying is used conventionally and broadly refers to processes involving breaking up liquid mixtures into small droplets (atomization) and rapidly removing solvent from the mixture in a container (spray-drying apparatus) where there is a strong driving force for evaporation of solvent from the droplets. The

20 strong driving force for solvent evaporation is generally provided by maintaining the partial pressure of solvent in the spray-drying apparatus well below the vapor pressure of the solvent at the temperature of the drying droplets. This is accomplished by either (1) maintaining the pressure in the spray-drying apparatus at a partial vacuum (e.g., 0.01 to 0.50 atm); (2) mixing the liquid droplets with a warm

25 drying gas; or (3) both. For example, a solution of drug and HPMCAS in acetone can be suitably spray-dried by spraying the solution at a temperature of 50°C (the vapor pressure of acetone at 50°C is about 0.8 atm) into a chamber held at 0.01 to 0.2 atm total pressure by connecting the outlet to a vacuum pump. Alternatively, the acetone solution can be sprayed into a chamber where it is mixed with nitrogen or

30 other inert gas at a temperature of 80°C to 180°C and a pressure of 1.0 to 1.2 atm.

Generally, the temperature and flow rate of the drying gas is chosen so that the HPMCAS/drug-solution droplets are dry enough by the time they reach the wall

of the apparatus that they are essentially solid, so that they form a fine powder and do not stick to the apparatus wall. The actual length of time to achieve this level of dryness depends on the size of the droplets. Droplet sizes generally range from 1 μm to 500 μm in diameter, with 5 to 100 μm being more typical. The large surface-to-volume ratio of the droplets and the large driving force for evaporation of solvent leads to actual drying times of a few seconds or less. This rapid drying is critical to the particles maintaining a uniform, homogeneous composition instead of separating into drug-rich and polymer-rich phases. Such dispersions which have a homogeneous composition can be considered solid solutions and may be supersaturated in drug. Such homogeneous dispersions are preferred in that the MSSC value obtained when a large amount of drug is dosed can be higher for such dispersions relative to dispersions for which at least a portion of the drug is present as a drug-rich amorphous or crystalline phase. Solidification times should be less than 20 seconds, preferably less than 5 seconds, and more preferably less than 2 seconds. In general, to achieve this rapid solidification of the drug/polymer solution, it is preferred that the size of droplets formed during the spray drying process are less than 100 μm in diameter, preferably less than 50 μm in diameter, and more preferably less than 25 μm in diameter. The resultant solid particles thus formed are generally less than 100 μm in diameter, preferably less than 50 μm in diameter, more preferably less than 25 μm in diameter.

Following solidification, the solid powder may stay in the spray-drying chamber for 5 to 50 seconds, further evaporating solvent from the solid powder. The final solvent content of the solid dispersion as it exits the dryer should be low, since this reduces the mobility of drug molecules in the dispersion, thereby improving its stability. Generally, the residual solvent content of the dispersion should be less than 10 wt% and preferably less than 2 wt %.

The dispersions can then be post-processed to prepare them for administration using methods known in the art such as roller compaction, fluid bed agglomeration, or spray coating.

Spray-drying processes and spray-drying equipment are described generally in Perry's *Chemical Engineers' Handbook*, Sixth Edition (R. H. Perry, D. W. Green, J. O. Maloney, eds.) McGraw-Hill Book Co. 1984, page 20-54 to 20-57. More details

on spray-drying processes and equipment are reviewed by Marshall ("Atomization and Spray-Drying," Chem. Eng. Prog. Monogr. Series, 50 [1954] 2).

The solution spray-dried to form the HPMCAS/drug dispersion can contain only drug and HPMCAS in a solvent. Typically, the ratio of drug to HPMCAS in the solution ranges from 1 to 0.2 to 1 to 100 and preferably ranges from 1 to 0.4 to 1 to 20. However, when the drug dose is low (less than 20 mg), the drug-to-HPMCAS ratio can be even higher than 20. Essentially, solvents suitable for spray-drying can be any organic compound in which the drug and HPMCAS are mutually soluble. Preferably, the solvent is also volatile with a boiling point of 150°C or less. Preferred solvents include alcohols such as methanol, ethanol, n-propanol, iso-propanol, and butanol; ketones such as acetone, methyl ethyl ketone and methyl iso-butyl ketone; esters such as ethyl acetate and propylacetate; and various other solvents such as acetonitrile, methylene chloride, toluene, and 1,1,1-trichloroethane. Lower volatility solvents such as dimethyl acetamide or dimethylsulfoxide can also be used. Mixtures of solvents can also be used, as can mixtures with water as long as the polymer and HPMCAS are sufficiently soluble to make the spray-drying process practical.

Spray-dried solutions and the resulting dispersions can also contain various additives that aid in the stability, dissolution, tableting, or processing of the dispersion. As mentioned previously, examples of such additives include: surfactants, pH-controlling substances (e.g., acids, bases, buffers), fillers, disintegrants, or binders. Such additives can be added directly to the spray-drying solution such that the additive is dissolved or suspended in the solution as a slurry. Alternatively, such additives can be added following the spray-drying process to aid in forming the final dosage form.

In a further aspect this invention provides an *in vitro* test for evaluating the performance of HPMCAS candidate dispersion compositions, thereby allowing the identification of dispersion compositions that will yield good *in vivo* bioavailability of drug when taken orally. It has been determined that *in vitro* dissolution of a dispersion in model-fasted duodenal (MFD) solution is a good indicator of *in vivo* performance and bioavailability. In particular, a candidate dispersion can be dissolution tested by adding it to MFD solution and agitating to assist in dissolution.

In this test, the amount of dispersion is chosen such that if all drug dissolves, a 1.5-fold or greater supersaturated solution is obtained. A dispersion is within the scope of this invention if the maximum supersaturated concentration of drug exceeds, by a factor of at least 1.5, the equilibrium concentration of a control composition

- 5 comprising an equivalent quantity of undispersed drug. As previously discussed, the comparison composition is conveniently the undispersed drug alone (e.g., pure drug in its equilibrium state - either crystalline or amorphous) or the undispersed drug plus a weight of inert diluent equivalent to the weight of HPMCAS in the test composition. Preferably the supersaturated concentration of drug achieved with the test
- 10 dispersion exceeds the equilibrium drug concentration by a factor of at least three, and most preferably by a factor of at least five.

- A typical test can be conducted by (1) dissolving a sufficient quantity of control composition, typically the candidate drug alone, to achieve equilibrium drug concentration; (2) dissolving a sufficient quantity of test dispersion to achieve a
- 15 maximum supersaturated drug concentration; and (3) determining whether the supersaturated concentration exceeds the equilibrium concentration by a factor of at least 1.5. The concentration of dissolved drug is typically measured as a function of time by sampling the solution and plotting concentration vs. time so that the concentration maximum can be ascertained. For purposes of avoiding drug
- 20 particulates which would give an erroneous determination in the test, the test solution is either filtered or centrifuged. "Dissolved drug" is typically taken as that material that either passes a 0.45 μm syringe filter or, alternatively, that material that remains in the supernatant following centrifugation. Filtration can be conducted using a 13 mm, 0.45 μm polyvinylidene difluoride syringe filter sold by Scientific
- 25 Resources under the trademark Titan[®]. Centrifugation is typically carried out in a polypropylene microcentrifuge tube by centrifuging at 13,000 G for 60 seconds using any centrifuge suitable for the purpose. Other similar filtration or centrifugation methods can be employed and useful results obtained. For example, using other types of microfilters may yield values somewhat higher or lower (plus or minus 10 to
- 30 40%) than that obtained with the filter specified above but will still allow identification of suitable dispersions.

Dispersions can also be tested in dogs as follows:

Beagle dogs (typically n=4-6) that have been fasted the previous day are administered the formulation in the fasted or fed state (fasted state: no food is allowed until after an 8 hr blood sample; fed state: a meal of 14 g of dry dog food and 8 g of olive oil (this meal imitates the high fat "FDA breakfast") immediately before dosing test or control composition, and regular rations after the 8 hr sample).

The test and control formulations are administered via oral gavage in water or 0.2% aqueous polysorbate 80 to aid in wetting, through PE205 tubing attached to a syringe. Dogs are returned to metabolism cages with normal access to water. Alternatively, dosing may be via capsules or tablets, with the provision that the test and control formulations be identical, except for the presence or absence of HPMCAS.

Blood samples are taken from the jugular vein using a 10 ml disposable syringe with a 20 gauge needle at 0.5, 1, 1.5, 2, 3, 4, 6, 8 (and occasionally 12 hr) hours post dose. Other sampling times may be used with the conditions that T_{max} is bracketed by the sampling intervals and that an accurate AUC may be calculated.

Samples are immediately transferred to clean glass culture tubes containing heparin.

Samples are centrifuged at room temperature at 3000 rpms for 5 minutes. Plasma is transferred to clean glass 1 dram vials using a 5 1/4" pasteur pipette. Plasma samples are frozen on dry ice and stored in a laboratory freezer until assayed by HPLC.

From plasma or serum drug concentrations, typical pharmacokinetic parameters, such as C_{max} , T_{max} and AUC are calculated for each dog, and then averaged for the test population.

Dispersions can be tested *in vivo* in humans as follows. In a crossover design, 4 or more healthy human subjects are dosed with a suspension of crystalline drug (or amorphous drug if the drug does not crystallize) or a suspension of drug/HPMCAS spray-dried dispersion. Blood samples are taken before dosing and at a variety of times post-dosing, with the number and temporal distribution of sampling times chosen to bracket T_{max} and permit accurate measurement of AUC.

Drug concentration in plasma or serum is measured by an appropriate assay, and C_{max} , T_{max} , and AUC are determined. A dispersion of this invention is a spray-dried drug/HPMCAS dispersion which, when tested in an animal species:

(a) exhibits a drug C_{\max} which is greater than 1.25-fold the C_{\max} determined after dosing crystalline drug alone (or amorphous drug if the drug does not crystallize), or

(b) exhibits a drug AUC which is greater than 1.25-fold the AUC determined after dosing crystalline drug alone (or amorphous drug if the drug does not crystallize).

Preferred drug/HPMCAS dispersions are those which satisfy both the (a) and (b) criteria above.

Compositions of this invention can be used in a wide variety of forms for administration of drugs orally. Exemplary dosage forms are powders or granules that can be taken orally either dry or reconstituted by addition of water to form a paste, slurry, suspension or solution; tablets, capsules, or pills. Various additives can be mixed, ground, or granulated with the compositions of this invention to form a material suitable for the above dosage forms. Potentially beneficial additives fall generally into the following classes: other matrix materials or diluents, surface active agents, drug complexing agents or solubilizers, fillers, disintegrants, binders, lubricants, and pH modifiers (e.g., acids, bases, or buffers).

Examples of other matrix materials, fillers, or diluents include lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch.

Examples of surface active agents include sodium lauryl sulfate and polysorbate 80.

Examples of drug complexing agents or solubilizers include the polyethylene glycols, caffeine, xanthene, gentisic acid and cyclodextrins.

Examples of disintegrants include sodium starch glycolate, sodium alginate, carboxymethyl cellulose sodium, methyl cellulose, and croscarmellose sodium.

Examples of binders include methyl cellulose, microcrystalline cellulose, starch, and gums such as guar gum, and tragacanth.

Examples of lubricants include magnesium stearate and calcium stearate.

Examples of pH modifiers include acids such as citric acid, acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, phosphoric acid, and the like; bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like, and buffers generally comprising mixtures of acids and the salts of said

acids. At least one function of inclusion of such pH modifiers is to control the dissolution rate of the drug, matrix polymer, or both, thereby controlling the local drug concentration during dissolution. In some cases it has been determined that the MSSC values for some drugs are higher when the solid amorphous drug dispersion
5 dissolves relatively slowly rather than fast, e.g., over 60 to 180 minutes rather than less than 60 minutes.

As was stated earlier, additives may be incorporated into the solid amorphous dispersion during or after its formation.

In addition to the above additives or excipients, use of any conventional
10 materials and procedures for formulation and preparation of oral dosage forms using the compositions of this invention known by those skilled in the art are potentially useful.

Other features and embodiments of the invention will become apparent by the following examples which are given for illustration of the invention rather than
15 limiting its intended scope. In the examples, reference is made to a mini spray dryer (schematically illustrated in Figure 1) and to a micro spray dryer, schematically illustrated in Figure 2. These spray dryers were adapted from commercially available spray dryers sold by NIRO to downsize them to a size suitable for laboratory scale production of spray dried drug products.

In the Examples, "mgA" is an acronym for "milligrams of active drug", i.e., the
20 non-salt free base or free acid if the compound is ionizable. "µgA" similarly means micrograms of active drug.


The mini spray-dryer shown in Figure 1 consists of an atomizer in the top cap of a vertically oriented stainless steel pipe shown generally as 10. The atomizer is a
25 two-fluid nozzle (Spraying Systems Co. 1650 fluid cap and 64 air cap) where the atomizing gas is nitrogen delivered through line 12 to the nozzle at 100°C and a flow of 15 gm/min, and a test solution to be spray dried is delivered through line 14 to the nozzle at room temperature and a flow rate of 1.0 gram/min using a syringe pump (Harvard Apparatus, Syringe Infusion Pump 22, not shown). Filter paper 16 with a
30 supporting screen (not shown) is clamped to the bottom end of the pipe to collect the solid spray-dried material and allow the nitrogen and evaporated solvent to escape.

The micro spray dryer shown in Figure 2 consists of an atomizer 102 in the top of a vacuum flask 100 kept at 40 °C by a water bath 104. Atomizer 102 is a two-

fluid spray nozzle (NIRO Aeromatic, 2.7 mm ID air cap, 1.0 mm ID fluid cap) where the atomizing gas is nitrogen delivered to the nozzle at ambient temperature and at 20 psi, and the drug/polymer test solution 106 is delivered to nozzle 102 at 40 °C at a flow rate of 1.0 gm/min using a peristaltic pump 108 (Masterflex, model 7553-60, with pump head #7013-20, and Norprene tubing #6404-13). Microporous cellulose extraction thimble 110 (Whatman Filter Co.) is mounted in a vacuum trap 114 to collect the solid spray-dried material, and a vacuum of 400 mbar (monitored by vacuum gauge 112) is pulled on the system by means of vacuum pump 116, which aids in solvent evaporation.

Example 1

A solution of compound and polymer was made by dissolving 133.0 mg of [R-(R*,S*)]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1-H-indole-2-carboxamide (Compound 1, shown below) and 67.0 mg of HPMCAS-MF (Shin Etsu, containing 23.4% methoxyl, 7.2% hydroxypropyl, 9.4% acetyl, 11.0% succinoyl, MW = 8.0×10^4 , Mn = 4.4×10^4) in 10 gm of HPLC grade acetone (Burdick & Jackson). The compound/polymer solution was then placed in a 20 mL syringe that was then inserted into a syringe pump.



Compound 1

Solvent was rapidly removed from the above solution by spraying it into the mini spray-drying apparatus shown in Figure 1, referred to herein as the “mini” spray dryer. The resulting material was a dry, white, substantially amorphous powder.

5 Example 2

This example discloses an *in vitro* dissolution test termed the “syringe/filter” method. In this method the concentration of test compound in solution is determined as a function of time. Test solution is held in a syringe from which samples are
10 expelled through a filter at pre-determined time points. In between expelling samples from the syringe, the syringe is rotated (50 rpm) on a wheel held in an oven at 37°C.

7.5 mg of the material of Example 1 was placed in an empty disposable 10 mL syringe (Aldrich, Fortuna). A 20 GA hypodermic needle was attached to the
15 syringe, and 10 mL of a model-fasted duodenal (MFD) solution at 37°C was drawn into the syringe. The MFD solution was composed of phosphate-buffered saline solution (82 mM NaCl, 20 mM Na₂HPO₄, 47 mM KH₂PO₄, pH 6.5, 290 mOsm/kg) containing 14.7 mM sodium taurocholate (Fluka) and 2.8 mM 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids).

20 The MFD solution was prepared using the following procedure. Into a 100 mL round bottom flask was weighed 0.788 gm of the sodium taurocholic acid, which was then dissolved in 5.0 mL of ambient HPLC methanol (Burdick & Jackson). To this solution was added 15.624 gm of the 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine in chloroform, supplied by Avanti Polar Lipids as a 20 mg/mL
25 solution. This mixture was then mixed thoroughly by vortex mixer (Fisher Vortex Genie), and the solvent removed rapidly by roto-evaporator (Rotavapor RE121, Büchi), leaving a dry white surface dispersion coating the flask. The surface dispersion was then reconstituted with 200 mL of the 37 °C phosphate buffered saline.

30 The needle was then replaced with a 13 mm, 0.45 µm polyvinylidene difluoride syringe filter (Scientific Resources, Titan), and the syringe was vigorously shaken for 30 sec. After 30 sec, 6 drops of the solution was expelled and a subsequent 13 drop sample was delivered to a test tube. After expelling the sample,

the syringe plunger was drawn back to pull an air bubble into the syringe to aid in subsequent mixing and the syringe placed back on a rotating wheel in a 37°C oven. The sample was diluted 1:1 with a solution containing 60/40- 1.7 wt% ammonium ascorbate in acetonitrile, and the concentration of compound analyzed on an HPLC (Hewlett Packard 1090 HPLC, Phenomenex Ultracarb ODS 20 analytical column, absorbance measured at 215 nm with a diode array spectrophotometer). The remaining solution in the syringe was mixed by rotating on a wheel at 50 rpm in a 37°C temperature-controlled box.

Samples were taken after 5, 30, 60 and 180 minutes as described above, analyzed, and compound concentrations calculated. The concentration of compound in the filtrate as a function of elapsed time (time=0 when the solid material of Example 1 is first mixed with aqueous solution) was found to be 17 µgA/ml at 5 min., 70 µgA/ml at 10 min., 120 µgA/ml at 30 min., 127 µgA/ml at 60 min and 135 µgA/ml at 180 min., and 38 µgA/ml at 1200 min. (see Table I, Example 9). This result showed that the HPMCAS/Compound 1 solid amorphous dispersion rapidly yields a high concentration of dissolved compound (at least 12-fold higher than its equilibrium solubility of 9 µgA/ml) in the dissolution medium and this supersaturated concentration was maintained for at least 180 minutes. When crystalline compound was triturated and subjected to the same dissolution test, a maximum concentration of Compound 1 of 10 µgA/ml was obtained (See Comparative Example 1). Throughout the examples, triturated material indicates that the material was ground lightly by hand for 60 seconds using a mortar and pestle.

Example 3

This example discloses an *in vitro* dissolution test termed the "centrifuge" method. This method was used to test the dissolution of material made by essentially the same method as that described in Example 1 except that the concentration of Compound 1 was decreased by a factor of 2 to 66.5 mg such that the ratio of compound to polymer was 1:1. (see Example 7, Table I).

In a 37°C controlled temperature box, 1.8mg of solid product from Example 1 was accurately weighed into an empty microcentrifuge tube (polypropylene, Sorenson Bioscience Inc.). The theoretical maximum concentration of compound in

solution (e.g., if all compound dissolved) was 383 $\mu\text{gA/ml}$ [1.8 mg dispersion (1000 $\mu\text{g/1 mg}$) (0.5 $\mu\text{g compound}/\mu\text{g dispersion}$) (0.764 compound assay)/1.8 ml = 393 $\mu\text{gA/ml}$]. This value is termed the theoretical maximum supersaturated concentration and is abbreviated Theoretical MSSC. 1.8 mL of a 37C phosphate buffered saline solution (8.2mM NaCl, 1.1mM Na₂HPO₄, 4.7mM KH₂PO₄, pH 6.5, 290mOsm/kg)containing 14.7mM sodium taurocholic acid (Fluka) and 2.8mM 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids) was added to the tube. The centrifuge tube was closed and a timer was started. The tube was then mixed continuously at the highest speed on a vortex mixer (Fisher Vortex Genie 2) for 60 seconds. The tube was transferred to a centrifuge (Marathon, Model Micro A) allowed to stand undisturbed for six minutes, then centrifuged at 13,000 G for 60 seconds. A 25 uL sample was removed from the solids-free supernatant in the centrifuge tube via pipette (Gilson Pipetman P-100) ten minutes after the timer was started. Solids in the centrifuge tube were resuspended by mixing the sample continuously on the vortex mixer for 30 seconds. The centrifuge tube was returned to the centrifuge and allowed to stand undisturbed until the next sample was taken. Each sample was centrifuged, sampled and resuspended as described previously. Each sample was diluted 1:1 with a solution containing 60/40 1.7wt% ammonium ascorbate/acetonitrile, and the concentration of compound was determined by HPLC (Hewlett Packard 1090 HPLC, Phenomenex Ultracarb ODS 20 analytical column, absorbance measured at 215 nm with a diode array spectrophotometer). Samples were taken after 10, 30, 60, 180, and 1,200 minutes as described above, analyzed and compound concentrations were calculated. The concentration of compound in the supernatant solution for the times listed above were 96, 121, 118, 125, and 40 $\mu\text{gA/ml}$, respectively. The composition and performance data is summarized in Table I as Example 7. The maximum compound concentration observed, 125 $\mu\text{gA/ml}$, is termed the maximum supersaturated concentration of compound and is abbreviated MSSC.

Table I

EXAMPLE NO.	Drug No.	Polymer Type	Dg:Poly Ratio	Sprayer	Analytical Method	Theor. MSSC (µgA/mL)	MSSC (µgA/mL)	C ₉₀ (µgA/mL)	C ₁₂₀₀ (µgA/mL)	C ₁₈₀ (µgA/mL)
5	1	HPMCAS-MF	1:1	MINI	syringe/filter	500	120	117	14	120
6	1	HPMCAS-HF	1:1	MINI	syringe/filter	500	82	80	20	82
7	1	HPMCAS-MF	1:1	MICRO	centrifuge	383	125	118	40	125
8	1	HPMCAS-MF	1:1	MICRO	syringe/filter	500	120	116	100	120
9	1	HPMCAS-MF	1:0.5	MINI	syringe/filter	500	135	130	38	135
10	1	HPMCAS-MF	1:1	MICRO	syringe/filter	500	117	115	36	115
11	1	HPMCAS-MF	1:2	MICRO	syringe/filter	500	112	110	39	100
12	1	HPMCAS-MF	1:5	MICRO	syringe/filter	500	108	96	96	96
13	1	HPMCAS-MF	1:9	MICRO	syringe/filter	89	86	82	85	83
14	1	HPMCAS-MF	1:9	MINI	syringe/filter	545	520	333	520	399

Example 4

A solution of compound and polymer was made by dissolving 200.0 mg of [R-(R*,S*)]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-

5 (phenylmethyl)propyl]-1-H-indole-2-carboxamide (Compound 1) and 1.8 gm of HPMCAS-MF (Shin Etsu, containing 23.4% methoxyl, 7.2% hydroxypropyl, 9.4% acetyl, 11.0% succinoyl, MW = 8.0×10^4 , Mn = 4.4×10^4) in 118 gm of HPLC grade acetone (Burdich & Jackson). The compound/polymer solution was then spray-dried.

10 Solvent was rapidly removed from the above solution by spraying it into the spray-drying apparatus shown in Figure 2, the "micro" spray dryer. The resulting material was a dry, white, substantially amorphous powder.

Examples 5 to 14

15 Spray-dried dispersions of Compound 1 exemplifying the invention were made as described in Example 1 (Mini Spray-dryer) or Example 4 (Micro Spray-dryer) except as noted in Table I. The dispersions were tested by the method described in Example 2 or Example 3 as noted in Table I and the results are
20 tabulated in Table I.

Comparative Examples C1 to C4

25 The following tests of Compound 1 were conducted to aid in demonstrating the superior solubilities of dispersions according to the invention relative to conventional forms of Compound 1. Dissolution tests were conducted using the syringe/filter test described in Example 2 with four materials: 1) triturated crystalline compound alone (Example C1), 2) a solid spray-dried dispersion of Compound 1
30 and PVAP (Example C2), 3) a solid spray-dried dispersion of Compound 1 and HPMCP (Example C3), and 4) a solid spray-dried dispersion of Compound 1 and PVP (Example C4). The composition of each material and the results of the dissolution tests are listed in Table II and should be compared to Examples 5 to 14 in Table I. All HPMCAS dispersions showed much higher concentrations of dissolved
35 compound (80 to 520 $\mu\text{gA/ml}$) than the crystalline compound alone (10 $\mu\text{gA/ml}$) and

the compound concentration even after 1200 minutes was 20 to 520 $\mu\text{gA/ml}$, at least twice the equilibrium solubility (i.e. 8 to 10 $\mu\text{gA/ml}$). In addition it can be seen that although dispersions composed of matrix polymers other than HPMCAS (PVAP, HPMCP, PVP) show supersaturation, this super saturation is not maintained as well
5 as with HPMCAS (C_{1200} values are approximately equal to equilibrium solubility (9 to 13 $\mu\text{gA/ml}$) while C_{1200} values for HPMCAS dispersions are generally 40 to 520 $\mu\text{gA/ml}$).

Table II. Comparative Examples for Compound No. 1

Example No.	Cpd No.	Polymer Type	Cpd Polymer Ratio	Sprayer	Dissolution Test Method	Theor. MSSC (µgA/mL)	MSSC (µgA/mL)	C90 (µgA/mL)	C1200 (µgA/mL)	C180 (µgA/mL)
C1	1	NONE	1:0	TRITURATED	syringe/filter	98	10	10	9	8.5
C2	1	PVAP	1:1	MINI	syringe/filter	500	104	82	9	17
C3	1	HPMCP	1:1	MINI	syringe/filter	500	127	123	13	106
C4	1	PVP	1:1	MINI	syringe/filter	500	133	125	13	114

Example 15

In this example, a solid amorphous dispersion of Compound 1 was prepared using a relatively large spray dryer that produces dispersions at a rate of about 0.5 to 1.0 g/min. A compound/polymer solution was made by dissolving 6 g of Compound 1 and 3 g HPMCAS-MF in 600 g of acetone. The compound/polymer solution was then placed in a pressure vessel that delivers the compound/polymer solution at a controlled rate to a commercial spray dryer. (Mobile Minor Hi-Tec for Non-Aqueous Feed Spray Dryer, manufactured by NIRO A/S, Soburg, Denmark)


The Niro spray dryer consists of an atomizer that fits into the top of a drying chamber. The atomizer is a 2-fluid nozzle. The atomizing gas was nitrogen delivered to the nozzle at and a flow of 180 g/min. The Compound/polymer solution described above was delivered to the nozzle at room temperature at a rate of 45 g/min. Drying gas was delivered to the drying chamber through an inlet duct that surrounds the 2-fluid nozzle. The drying gas was nitrogen heated to 120°C and delivered to the drying chamber at 1500 s/min. The spray-dried material exited the chamber with the drying gas through transport ducts and into a cyclone. At the top of the cyclone is an exhaust vent that allows the nitrogen and evaporated solvent to escape. The spray-dried material was collected in a canister. The material was a dry, white, substantially amorphous powder.

This dispersion was tested by using the method described in Example 2. Sufficient dispersion was used in this test such that the theoretical maximum concentration of Compound 1 (if it all dissolved) was 500 µgA/ml. The maximum concentration of Compound 1 observed was 137 µgA/ml. Ninety minutes after the start of this test, the concentration of Compound 1 was 130 µgA/ml and at 1200 minutes the concentration was 22 µgA/ml. Comparison of these results to those for Example 9 in Table I show that the dispersion made on the large spray dryer performed similarly to that made on the "mini" spray dryer.

Examples 16 to 18

Spray-dried dispersions of Compound 2, 3,5-dimethyl-4-(3'-pentoxy)-2-(2',4',6'-trimethylphenoxy)pyridine, structure shown below, exemplifying the invention were made as described in Example 1 (Mini Spray-dryer), except as noted in Table III.

The dispersions were tested by the method described in Example 3 and noted in Table III and the results are tabulated in Table III.



Compound 2

Table III

EXAMPLE NO	Drug No	Polymer		Dg:Poly Ratio	Sprayer	Analytical Method	Theor. MSSC (µg/ml)	MSSC (µg/ml)	C ₅₀ (µg/ml)	C ₂₀₀ (µg/ml)	C ₅₀₀ (µg/ml)
		Type									
16	2	HMC	SHF	1:9	MN	centrifuge	95	73	69	46	—
17	2	HMC	SMF	1:9	MN	centrifuge	105	103	92	63	—
18	2	HMC	SMF	1:2	MN	centrifuge	100	66	54	51	—

Comparative Examples C5 and C6.

The following tests of Compound 2 in crystalline form either alone or simply triturated by hand (as described in Example 2) with HPMCAS are for comparison to

5 Examples 16 to 18 in Table III. The composition of the materials and the results of dissolution tests are shown in Table IV. Much higher compound concentrations were achieved with the HPMCAS dispersions relative to crystalline compound either alone or mixed (but not dispersed) in HPMCAS. This demonstrates that the compound should be dispersed in amorphous form in the HPMCAS according to this


10 invention instead of triturating the crystalline compound with HPMCAS to achieve high levels of supersaturation that are maintained for long time periods.

Table IV. Comparative Examples for Compound No. 2

Ex No.	Cpd No.	Polymer Type	Cpd Polymer Ratio	Sprayer	Dissolution Test Method	Theor. MSSC (µgA/mL)	MSSC (µgA/mL)	C90 (µgA/mL)	C1200 (µgA/mL)	C180 (µgA/mL)
C5	2	NONE	1:0	TRITURA TED	centrifuge	100	18	18	13	---
C6	2	HPMCAS-HF	1:9	TRITURA TED	centrifuge	85	12	12	---	---

Examples 19 to 22

- 5 Spray-dried dispersions of Compound 3, 5-(2-(4-(3-benzisothiazolyl)-piperazinyl)ethyl-6-chlorooxindole (ziprasidone), shown below, exemplifying the invention were made as described in Example 1 (Mini Spray-dryer) except as noted in Table V. The dispersions were tested by the method described in Example 3 as noted in Table V and the results are tabulated in Table V.



Compound 3

Table V

EXAMPLE NO.	Drug No.	Polymer Type	Dg:Poly* Ratio	Sprayer	Analytical Method	Theor. MSSC ($\mu\text{g}/\text{mL}$)	MSSC ($\mu\text{g}/\text{mL}$)	C ₅₀ ($\mu\text{g}/\text{mL}$)	C ₂₀₀ ($\mu\text{g}/\text{mL}$)	C ₁₈₀ ($\mu\text{g}/\text{mL}$)
19	3	HPMCAS-HF	1:9	MIN	centrifuge	189	98	59	-	-
20	3	HMP-CAS-HF	1:5	MIN	centrifuge	162	101	40	11	-
21	3	HPMCAS-MF	1:9	MIN	centrifuge	176	138	7	4	-
22	3	HPMCAS-LF	1:9	MIN	centrifuge	151	105	12	-	-

*Drug:Polymer ratio is based on total weight of hydrochloride salt.

Comparative Examples C7 and C8

The following tests of Compound 3 in crystalline form alone and triturated with HPMCAS are for comparison to Examples 19 to 22 in Table V. The

- 5 composition of the materials and the results of dissolution tests are shown in Table VI. The HPMCAS dispersions yielded much higher compound concentrations than either the crystalline compound alone or the crystalline compound triturated by hand with HPMCAS showing the excellent performance of the composition of the invention and the importance of dispersing the compound in HPMCAS in an amorphous form.
- 10 The results shown in Table V also demonstrate that for dispersions of Compound 3, HPMCAS-HF maintains a higher compound concentration (compare C_{90} values), compared to HPMCAS-MF and HPMCAS-LF.

Table VI. Comparative Examples for Compound No. 3

Ex No.	Cpd No.	Polymer Type	Cpd Polymer Ratio	Sprayer	Dissolution Test Method	Theor. MSSC (µgA/mL)	MSSC (µgA/mL)	C90 (µgA/mL)	C1200 (µgA/mL)	C180 (µgA/mL)
.										
C7	3	NONE	1:0	TRITURATED	centrifuge	180	27	4	1	---
C8	3	HPMCAS-HF	1:5	TRITURATED	centrifuge	176	37	29	4	---

Example 23

A dispersion of Compound 3 was made by dissolving 10 g of Compound 3 and 90 g of HPMCAS-HF in 2400 g methanol. This compound/polymer solution was spray-dried using the Niro spray dryer as described in Example 15. The compound/polymer solution was delivered to the 2-fluid nozzle at room temperature at a flow rate of 25 g/min. All other conditions were the same as those described in Example 15.

This dispersion was tested using the method described in Example 3 (the "centrifuge" method). Sufficient dispersion was tested such that the concentration of Compound 3 would be 200 $\mu\text{gA/ml}$ if all of the compound dissolved. The maximum compound concentration observed (C_{max}) was 107 $\mu\text{gA/ml}$. The compound concentration after 90 minutes and 1200 minutes was 60 $\mu\text{gA/ml}$ and 32 $\mu\text{gA/ml}$, respectively.

Example 24

A comparison of the performance of dispersions of the present invention (spray dried) with those prepared conventionally by slow evaporation of solvent was made as follows. A dispersion of the present invention (Example 24) was prepared from 500 grams of compound/polymer solution comprising 0.2 wt% Compound 3 and 1.8 wt% HPMCAS-HF in methanol (USP/NF grade) using the Niro spray dryer and procedure described in Example 23. 5.8 grams of spray-dried dispersion was recovered.

Comparative Examples C9 and C10

A conventional dispersion (Example C9) was prepared as follows. 100 grams of compound/polymer solution of the same composition as that used in Example 24 was placed in a 500 ml round-bottom flask. Solvent was removed from the solution at reduced pressure at 40°C using a rotary evaporator. After 30 minutes, the material appeared to be dry and it was scraped from the flask. The conventional dispersion was placed under vacuum for several hours to remove any traces of solvent. 1.8 grams of conventional dispersion was recovered.

5


Table VII.

Ex No.	Cpd No.	Polymer Type	Cpd Polymer Ratio	Drying Equipment	Dissolution Test Method	Theor. MSSC (µgA/mL)	C3 (µgA/mL)	C10 (µgA/mL)	C20 (µgA/mL)	C40 (µgA/mL)
24	3	HPMCA S-HF	1:9	Niro Spray Dryer	centrifuge	195	128	98	75	47
C9	3	HPMCA S-HF	1:9	rotary evaporator	centrifuge	204	0	0	0	3.9
C10	3	NONE	1:0	--	centrifuge	180	27	22	19	7

Examples 25 to 27

Spray-dried dispersions of Compound 4, Griseofulvin, 7-chloro-4,6-dimethoxy-courmaran-3-one-2-spiro-1'-(2'-methoxy-6'-methylcyclohex-2'en-4'-one),
5 shown below, exemplifying the invention were made as described in Example 4 (Micro Spray-dryer) except as noted in Table VIII. The dispersions were tested by the method described in Example 2 as noted in Table VIII and the results are tabulated in Table VIII.

10



Compound 4

Table VIII

EXAMPLE NO	Drug No	Polymer Type	DgtPoly Ratio	Sprayer	Analytical Method	Theor. MSSC (µgA/ml)	MSSC (µgA/ml)	C ₈₀ (µgA/ml)	C ₁₂₀ (µgA/ml)	C ₁₈₀ (µgA/ml)
25	4	HPMCASMF	1:9	MORO	syringe filter	200	186	175	125	175
26	4	HPMCASMF	1:4	MORO	syringe filter	200	175	166	-	160

Comparative Example C11

- This example shows the results of a dissolution test of Compound 4 in its crystalline form in Table IX for comparison with Examples 25 to 27, Table VIII. Much
- 5 higher compound concentrations are achieved with the HPMCAS dispersions than with crystalline compound alone.


TABLE VIII
Dissolution of Compound 4 in water at 37°C
Time (min) 0 15 30 45 60 75 90 105 120 135 150 165 180 195 210 225 240 255 270 285 300 315 330 345 360 375 390 405 420 435 450 465 480 495 510 525 540 555 570 585 600 615 630 645 660 675 690 705 720 735 750 765 780 795 810 825 840 855 870 885 900 915 930 945 960 975 990 1005 1020 1035 1050 1065 1080 1095 1110 1125 1140 1155 1170 1185 1200 1215 1230 1245 1260 1275 1290 1305 1320 1335 1350 1365 1380 1395 1410 1425 1440 1455 1470 1485 1500 1515 1530 1545 1560 1575 1590 1605 1620 1635 1650 1665 1680 1695 1710 1725 1740 1755 1770 1785 1800 1815 1830 1845 1860 1875 1890 1905 1920 1935 1950 1965 1980 1995 2010 2025 2040 2055 2070 2085 2100 2115 2130 2145 2160 2175 2190 2205 2220 2235 2250 2265 2280 2295 2310 2325 2340 2355 2370 2385 2400 2415 2430 2445 2460 2475 2490 2505 2520 2535 2550 2565 2580 2595 2610 2625 2640 2655 2670 2685 2700 2715 2730 2745 2760 2775 2790 2805 2820 2835 2850 2865 2880 2895 2910 2925 2940 2955 2970 2985 3000 3015 3030 3045 3060 3075 3090 3105 3120 3135 3150 3165 3180 3195 3210 3225 3240 3255 3270 3285 3300 3315 3330 3345 3360 3375 3390 3405 3420 3435 3450 3465 3480 3495 3510 3525 3540 3555 3570 3585 3600 3615 3630 3645 3660 3675 3690 3705 3720 3735 3750 3765 3780 3795 3810 3825 3840 3855 3870 3885 3900 3915 3930 3945 3960 3975 3990 4005 4020 4035 4050 4065 4080 4095 4110 4125 4140 4155 4170 4185 4200 4215 4230 4245 4260 4275 4290 4305 4320 4335 4350 4365 4380 4395 4410 4425 4440 4455 4470 4485 4500 4515 4530 4545 4560 4575 4590 4605 4620 4635 4650 4665 4680 4695 4710 4725 4740 4755 4770 4785 4800 4815 4830 4845 4860 4875 4890 4905 4920 4935 4950 4965 4980 4995 5010 5025 5040 5055 5070 5085 5100 5115 5130 5145 5160 5175 5190 5205 5220 5235 5250 5265 5280 5295 5310 5325 5340 5355 5370 5385 5400 5415 5430 5445 5460 5475 5490 5505 5520 5535 5550 5565 5580 5595 5610 5625 5640 5655 5670 5685 5700 5715 5730 5745 5760 5775 5790 5805 5820 5835 5850 5865 5880 5895 5910 5925 5940 5955 5970 5985 6000 6015 6030 6045 6060 6075 6090 6105 6120 6135 6150 6165 6180 6195 6210 6225 6240 6255 6270 6285 6300 6315 6330 6345 6360 6375 6390 6405 6420 6435 6450 6465 6480 6495 6510 6525 6540 6555 6570 6585 6600 6615 6630 6645 6660 6675 6690 6705 6720 6735 6750 6765 6780 6795 6810 6825 6840 6855 6870 6885 6900 6915 6930 6945 6960 6975 6990 7005 7020 7035 7050 7065 7080 7095 7110 7125 7140 7155 7170 7185 7200 7215 7230 7245 7260 7275 7290 7305 7320 7335 7350 7365 7380 7395 7410 7425 7440 7455 7470 7485 7500 7515 7530 7545 7560 7575 7590 7605 7620 7635 7650 7665 7680 7695 7710 7725 7740 7755 7770 7785 7800 7815 7830 7845 7860 7875 7890 7905 7920 7935 7950 7965 7980 7995 8010 8025 8040 8055 8070 8085 8100 8115 8130 8145 8160 8175 8190 8205 8220 8235 8250 8265 8280 8295 8310 8325 8340 8355 8370 8385 8400 8415 8430 8445 8460 8475 8490 8505 8520 8535 8550 8565 8580 8595 8610 8625 8640 8655 8670 8685 8700 8715 8730 8745 8760 8775 8790 8805 8820 8835 8850 8865 8880 8895 8910 8925 8940 8955 8970 8985 9000 9015 9030 9045 9060 9075 9090 9105 9120 9135 9150 9165 9180 9195 9210 9225 9240 9255 9270 9285 9300 9315 9330 9345 9360 9375 9390 9405 9420 9435 9450 9465 9480 9495 9510 9525 9540 9555 9570 9585 9600 9615 9630 9645 9660 9675 9690 9705 9720 9735 9750 9765 9780 9795 9810 9825 9840 9855 9870 9885 9900 9915 9930 9945 9960 9975 9990 10005 10020 10035 10050 10065 10080 10095 10110 10125 10140 10155 10170 10185 10200 10215 10230 10245 10260 10275 10290 10305 10320 10335 10350 10365 10380 10395 10410 10425 10440 10455 10470 10485 10500 10515 10530 10545 10560 10575 10590 10605 10620 10635 10650 10665 10680 10695 10710 10725 10740 10755 10770 10785 10800 10815 10830 10845 10860 10875 10890 10905 10920 10935 10950 10965 10980 10995 11010 11025 11040 11055 11070 11085 11100 11115 11130 11145 11160 11175 11190 11205 11220 11235 11250 11265 11280 11295 11310 11325 11340 11355 11370 11385 11400 11415 11430 11445 11460 11475 11490 11505 11520 11535 11550 11565 11580 11595 11610 11625 11640 11655 11670 11685 11700 11715 11730 11745 11760 11775 11790 11805 11820 11835 11850 11865 11880 11895 11910 11925 11940 11955 11970 11985 12000 12015 12030 12045 12060 12075 12090 12105 12120 12135 12150 12165 12180 12195 12210 12225 12240 12255 12270 12285 12300 12315 12330 12345 12360 12375 12390 12405 12420 12435 12450 12465 12480 12495 12510 12525 12540 12555 12570 12585 12600 12615 12630 12645 12660 12675 12690 12705 12720 12735 12750 12765 12780 12795 12810 12825 12840 12855 12870 12885 12900 12915 12930 12945 12960 12975 12990 13005 13020 13035 13050 13065 13080 13095 13110 13125 13140 13155 13170 13185 13200 13215 13230 13245 13260 13275 13290 13305 13320 13335 13350 13365 13380 13395 13410 13425 13440 13455 13470 13485 13500 13515 13530 13545 13560 13575 13590 13605 13620 13635 13650 13665 13680 13695 13710 13725 13740 13755 13770 13785 13800 13815 13830 13845 13860 13875 13890 13905 13920 13935 13950 13965 13980 13995 14010 14025 14040 14055 14070 14085 14100 14115 14130 14145 14160 14175 14190 14205 14220 14235 14250 14265 14280 14295 14310 14325 14340 14355 14370 14385 14400 14415 14430 14445 14460 14475 14490 14505 14520 14535 14550 14565 14580 14595 14610 14625 14640 14655 14670 14685 14700 14715 14730 14745 14760 14775 14790 14805 14820 14835 14850 14865 14880 14895 14910 14925 14940 14955 14970 14985 15000 15015 15030 15045 15060 15075 15090 15105 15120 15135 15150 15165 15180 15195 15210 15225 15240 15255 15270 15285 15300 15315 15330 15345 15360 15375 15390 15405 15420 15435 15450 15465 15480 15495 15510 15525 15540 15555 15570 15585 15600 15615 15630 15645 15660 15675 15690 15705 15720 15735 15750 15765 15780 15795 15810 15825 15840 15855 15870 15885 15900 15915 15930 15945 15960 15975 15990 16005 16020 16035 16050 16065 16080 16095 16110 16125 16140 16155 16170 16185 16200 16215 16230 16245 16260 16275 16290 16305 16320 16335 16350 16365 16380 16395 16410 16425 16440 16455 16470 16485 16500 16515 16530 16545 16560 16575 16590 16605 16620 16635 16650 16665 16680 16695 16710 16725 16740 16755 16770 16785 16800 16815 16830 16845 16860 16875 16890 16905 16920 16935 16950 16965 16980 16995 17010 17025 17040 17055 17070 17085 17100 17115 17130 17145 17160 17175 17190 17205 17220 17235 17250 17265 17280 17295 17310 17325 17340 17355 17370 17385 17400 17415 17430 17445 17460 17475 17490 17505 17520 17535 17550 17565 17580 17595 17610 17625 17640 17655 17670 17685 17700 17715 17730 17745 17760 17775 17790 17805 17820 17835 17850 17865 17880 17895 17910 17925 17940 17955 17970 17985 18000 18015 18030 18045 18060 18075 18090 18105 18120 18135 18150 18165 18180 18195 18210 18225 18240 18255 18270 18285 18300 18315 18330 18345 18360 18375 18390 18405 18420 18435 18450 18465 18480 18495 18510 18525 18540 18555 18570 18585 18600 18615 18630 18645 18660 18675 18690 18705 18720 18735 18750 18765 18780 18795 18810 18825 18840 18855 18870 18885 18900 18915 18930 18945 18960 18975 18990 19005 19020 19035 19050 19065 19080 19095 19110 19125 19140 19155 19170 19185 19200 19215 19230 19245 19260 19275 19290 19305 19320 19335 19350 19365 19380 19395 19410 19425 19440 19455 19470 19485 19500 19515 19530 19545 19560 19575 19590 19605 19620 19635 19650 19665 19680 19695 19710 19725 19740 19755 19770 19785 19800 19815 19830 19845 19860 19875 19890 19905 19920 19935 19950 19965 19980 19995 20010 20025 20040 20055 20070 20085 20100 20115 20130 20145 20160 20175 20190 20205 20220 20235 20250 20265 20280 20295 20310 20325 20340 20355 20370 20385 20400 20415 20430 20445 20460 20475 20490 20505 20520 20535 20550 20565 20580 20595 20610 20625 20640 20655 20670 20685 20700 20715 20730 20745 20760 20775 20790 20805 20820 20835 20850 20865 20880 20895 20910 20925 20940 20955 20970 20985 21000 21015 21030 21045 21060 21075 21090 21105 21120 21135 21150 21165 21180 21195 21210 21225 21240 21255 21270 21285 21300 21315 21330 21345 21360 21375 21390 21405 21420 21435 21450 21465 21480 21495 21510 21525 21540 21555 21570 21585 21600 21615 21630 21645 21660 21675 21690 21705 21720 21735 21750 21765 21780 21795 21810 21825 21840 21855 21870 21885 21900 21915 21930 21945 21960 21975 21990 22005 22020 22035 22050 22065 22080 22095 22110 22125 22140 22155 22170 22185 22200 22215 22230 22245 22260 22275 22290 22305 22320 22335 22350 22365 22380 22395 22410 22425 22440 22455 22470 22485 22500 22515 22530 22545 22560 22575 22590 22605 22620 22635 22650 22665 22680 22695 22710 22725 22740 22755 22770 22785 22800 22815 22830 22845 22860 22875 22890 22905 22920 22935 22950 22965 22980 22995 23010 23025 23040 23055 23070 23085 23100 23115 23130 23145 23160 23175 23190 23205 23220 23235 23250 23265 23280 23295 23310 23325 23340 23355 23370 23385 23400 23415 23430 23445 23460 23475 23490 23505 23520 23535 23550 23565 23580 23595 23610 23625 23640 23655 23670 23685 23700 23715 23730 23745 23760 23775 23790 23805 23820 23835 23850 23865 23880 23895 23910 23925 23940 23955 23970 23985 24000 24015 24030 24045 24060 24075 24090 24105 24120 24135 24150 24165 24180 24195 24210 24225 24240 24255 24270 24285 24300 24315 24330 24345 24360 24375 24390 24405 24420 24435 24450 24465 24480 24495 24510 24525 24540 24555 24570 24585 24600 24615 24630 24645 24660 24675 24690 24705 24720 24735 24750 24765 24780 24795 24810 24825 24840 24855 24870 24885 24900 24915 24930 24945 24960 24975 24990 25005 25020 25035 25050 25065 25080 25095 25110 25125 25140 25155 25170 25185 25200 25215 25230 25245 25260 25275 25290 25305 25320 25335 25350 25365 25380 25395 25410 25425 25440 25455 25470 25485 25500 25515 25530 25545 25560 25575 25590 25605 25620 25635 25650 25665 25680 25695 25710 25725 25740 25755 25770 25785 25800 25815 25830 25845 25860 25875 25890 25905 25920 25935 25950 25965 25980 25995 26010 26025 26040 26055 26070 26085 26100 26115 26130 26145 26160 26175 26190 26205 26220 26235 26250 26265 26280 26295 26310 26325 26340 26355 26370 26385 26400 26415 26430 26445 26460 26475 26490 26505 26520 26535 26550 26565 26580 26595 26610 26625 26640 26655 26670 26685 26700 26715 26730 26745 26760 26775 26790 26805 26820 26835 26850 26865 26880 26895 26910 26925 26940 26955 26970 26985 27000 27015 27030 27045 27060 27075 27090 27105 27120 27135 27150 27165 27180 27195 27210 27225 27240 27255 27270 27285 27300 27315 27330 27345 27360 27375 27390 27405 27420 27435 27450 27465 27480 27495 27510 27525 27540 27555 27570 27585 27600 27615 27630 27645 27660 27675 27690 27705 27720 27735 27750 27765 27780 27795 27810 27825 27840 27855 27870 27885 27900 27915 27930 27945 27960 27975 27990 28005 28020 28035 28050 28065 28080 28095 28110 28125 28140 28155 28170 28185 28200 28215 28230 28245 28260 28275 28290 28305 28320 28335 28350 28365 28380 28395 28410 28425 28440 28455 28470 28485 28500 28515 28530 28545 28560 28575 28590 28605 28620 28635 28650 28665 28680 28695 28710 28725 28740 28755 28770 28785 28800 28815 28830 28845 28860 28875 28890 28905 28920 28935 28950 28965 28980 28995 29010 29025 29040 29055 29070 29085 29100 29115 29130 29145 29160 29175 29190 29205 29220 29235 29250 29265 29280 29295 29310 29325 29340 29355 29370 29385 29400 29415 29430 29445 29460 29475 29490 29505 29520 29535 29550 29565 29580 29595 29610 29625 29640 29655 29670 29685 29700 29715 29730 29745 29760 29775 29790 29805 29820 29835 29850 29865 29880 29895 29910 29925 29940 29955 29970 29985 30000 30015 30030 30045 30060 30075 30090 30105 30120 30135 30150 30165 30180 30195 30210 30225 30240 30255 30270 30285 30300 30315 30330 30345 30360 30375 30390 30405 30420 30435 30450 30465 30480 30495 30510 30525 30540 30555 30570 30585 30600 30615 30630 30645 30660 30675 30690 30705 30720 30735 30750 30765 30780 30795 30810 30825 30840 30855 30870 30885 30900 30915 30930 30945 30960 30975 30990 31005 31020 31035 31050 31065 31080 31095 31110 31125 31140 31155 31170 31185 31200 31215 31230 31245 31260 31275 31290 31305 31320 31335 31350 31365 31380 31395 31410 31425 31440 31455 31470 31485 31500 31515 31530 31545 31560 31575 31590 31605 31620 31635 31650 31665 31680 31695 31710 31725 31740 31755 31770 31785 31800 31815 31830 31845 31860 31875 31890 31905 31920 31935 31950 31965 31980 31995 32010 32025 32040 32055 32070 32085 32100 32115 32130 32145 32160 32175 32190 32205 32220 32235

Table IX. Comparative Examples for Compound No. 4

Example No.	Cpd No.	Polymer Type	Cpd: Polymer Ratio	Sprayer	Dissolution Test Method	Theor. MSSC (µgA/mL)	MSSC (µgA/mL)	C60 (µgA/mL)	C90 (µgA/mL)	C180 (µgA/mL)
C11	4	NONE	1:0	TRITURATED	syringe/filter	200	18	17	15	---

Example 28

A spray-dried dispersion of Compound 5, nifedipine, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylic acid dimethyl ester, structure shown below, exemplifying the invention was made as described in Example 4 (Micro Spray-dryer) except as noted in Table X. The dispersion was tested by the method described in Example 2 as noted in Table X and the results are tabulated in Table X.



Compound 5

Table X

EXAMPLE NO	Drug No	Polymer Type	Dg:Poly Ratio	Sprayer	Analytical Method	Theor. MSSC ($\mu\text{g}/\text{mL}$)	MSSC ($\mu\text{g}/\text{mL}$)	C ₈₀ ($\mu\text{g}/\text{mL}$)	C ₂₂₀ ($\mu\text{g}/\text{mL}$)	C ₄₈₀ ($\mu\text{g}/\text{mL}$)
28	5	HFMASMF	1:9	MCRO	syringe filter	100	105	90	88	95

Comparative Example C12

- 5 This example shows the results of a dissolution test of Compound 5 in its crystalline form in Table XI for comparison with Example 28. A much higher compound concentration is achieved and sustained for 1200 minutes with the HPMCAS dispersion relative to crystalline compound alone.

TABLE XI
Dissolution Test Results for Compound 5 in its Crystalline Form and HPMCAS Dispersion

Table XI. Comparative Examples for Compound No. 5

Example No.	Cpd No.	Polymer	Cpd: Polyme Ratio	Sprayer	Dissolution Test Method	Theor. MSSC (µgA/mL)	MSSC (µgA/mL)	C90 (µgA/mL)	C1200 (µgA/mL)	C180 (µgA/mL)
C12	5	NONE	1:0	TRITURATED	syringe/filter	100	19	18	19	19


Example 29 and Comparative Examples C13 and C14

A comparison of the performance of a dispersion of Compound 6, 5,5-diphenylhydantoin (phenytoin), shown below, and HPMCAS of the present invention (spray-dried) with those prepared conventionally by slow evaporation of solvent was made as follows. A dispersion of the present invention (Example 29) was prepared from 720 grams of a compound/polymer solution prepared by dissolving 0.10 wt% of Compound 6 (Aldrich) and 0.90 wt% HPMCAS-MF (Shin-Etsu) in acetone (HPLC grade). This compound/polymer solution was spray-dried using the Niro spray-dryer and procedure described in Example 23. 6.8 grams of spray-dried dispersion was recovered.

A conventional dispersion (Example C13) was prepared from 90 grams of a compound/polymer solution of the same composition as that used in Example 29 using the procedure described for Comparative Example C9 except that the solvent was evaporated at 30°C. After 30 minutes, the material coated the surface of the flask as a solid cake and it was scraped from the flask. 0.9 grams of product was recovered.

The two dispersions described above (Example 29 and Comparative Example C13) and crystalline compound (Comparative Example C14) were tested using the centrifuge method described in Example 3. The results of this test are listed in Table XII.

The results clearly show that over the first 40 minutes of dissolution that the dispersions of the present invention achieve significantly higher compound concentrations than either crystalline compound (Comparative Example C14) or the conventional dispersion (Comparative Example C13).




Compound 6

Table XII. Comparative Examples for Compound No. 6

Example No.	Cpd No.	Polymer	Cpd: Polymer Ratio	Sprayer	Dissolution Test Method	Theor. MSSC ($\mu\text{gA/mL}$)	C3 ($\mu\text{gA/mL}$)	C10 ($\mu\text{gA/mL}$)	C20 ($\mu\text{gA/mL}$)	C40 ($\mu\text{gA/mL}$)	C90 ($\mu\text{gA/mL}$)
29	6	HPMCAS -MF	1:9	Niro	centrifuge	96	97	96	90	97	99
C13	6	HPMCAS -MF	1:9	rotary evaporator	centrifuge	103	23	43	58	78	90
C14	6	NONE	1:0		centrifuge	100	14	20	28	34	50

Example 30 and Comparative Example C15

A spray-dried dispersion of Compound 7, (+)-N-{3-[3-(4-fluorophenoxy)phenyl]-2-cyclopenten-1-yl}-N-hydroxyurea, structure shown below, exemplifying the invention was made as described in Example 1 (Mini Spray-dryer) except as noted in Table XIII. The dispersion, along with crystalline Compound 7 (Comparative Example C15), were tested by the method described in Example 3 as noted in Table XIII and the results are tabulated in Table XIII. The observed concentration of Compound 7 was much higher for the dispersion relative to the crystalline compound.



Compound 7


Table XIII

EXAMPLE NO.	Drug No.	Polymer Type	Dg:Poly Ratio	Sprayer	Analytical Method	Theor. MSSC (µgA/mL)	MSSC (µgA/mL)	C ₈₀ (µgA/mL)	C ₁₂₀₀ (µgA/mL)	C ₁₈₀ (µgA/mL)
30	7	HPMCAS-HF	1:9	MINI	centrifuge	1045	550	320	220	—

Example 31 and Comparative Example C16

A spray-dried dispersion of Compound 8, [3, 6-dimethyl -2 - (2, 4 ,6-trimethyl-

5 invention was made as described in Example 1 (Mini Spray-dryer) except as noted in
Table XIV. The dispersion, along with crystalline Compound 8 (Comparative
Example C16), were tested by the method described in Example 3 and noted in
Table XIV and the results are tabulated in Table XIV. The observed concentration of
Compound 8 was much higher for the dispersion relative to the crystalline
10 compound.




Compound 8

Table XIV

EXAMPLE NO.	Drug No.	Polymer Type	Dg:Poly Ratio	Sprayer	Analytical Method	Theor. MSSC (µgA/mL)	MSSC (µgA/mL)	C ₃₀ (µgA/mL)	C ₁₂₀₀ (µgA/mL)	C ₁₈₀ (µgA/mL)
31	8	HPMCAS-LF	1:2	MINI	centrifuge	477	467	405	167	—
C16	8	None	1:0	—	centrifuge	500	22	22	22	—

Example 32 and Comparative Example C17

A spray-dried dispersion of Compound 9, 1H-Indole-2-carboxamide, 5-chloro-N-[3-(3,4-dihydroxy-1-pyrrolidiny)-2-hydroxy-3-oxo-1-(phenylmethnnyl)propyl]-, [R-[R*, S*-(cis)]]-, exemplifying the invention was made as described in Example 1 (Mini Spray-dryer) except as noted in Table XV. The dispersion, along with crystalline Compound 9 (Comparative Example C17), were tested by the method described in Example 3 as noted in Table XV and the results are tabulated in Table XV. The observed concentration of Compound 9 was much higher for the dispersion relative to the crystalline compound.



Compound 9

Table XV

EXAMPLE NO.	Drug No.	Polymer Type	DgPoly Ratio	Sprayer	Analytical Method	Theor. MSSC (µg/mL)	MSSC (µg/mL)	C ₆₀ (µg/mL)	C ₁₂₀₀ (µg/mL)
32	9	HPMCASMF	1:1	MN	centrifuge	515	515	475	515
C17	9	None	1:0	—	centrifuge	500	194	158	194

Example 33

This example demonstrates that spray-dried dispersions of Compound 1 and HPMCAS, when orally dosed to beagle dogs, give a higher systemic compound exposure (C_{max} and AUC) than observed after dosing an aqueous suspension of crystalline Compound 1. The following formulations were orally dosed:

Formulation A: Aqueous suspension of crystalline Compound 1 in 0.5% methylcellulose. Dosed 5mgA/kg at 2 ml/kg.

- 5 Formulation B Solution of Compound 1 at 10mgA/ml in polyethyleneglycol-400 (PEG-400). Dosed 10mg/kg at 1ml/kg.

Formulation C:

- 10 Aqueous suspension of a 1:1 (w/w) Compound 1/HPMCAS spray-dried dispersion at 2.5mgA/ml in 2% polysorbate-80. Dosed at 3.7 mgA/kg at 2ml/kg.

Formulation D:

- 15 Capsule (size#2) containing 53.1 mgA Compound 1 as a 1:1 (w/w) Compound 1/HPMCAS spray-dried dispersion. The capsule fill composition is presented in Table XVI.

Formulation E:

- 20 Capsule (size #0) containing 200 mgA Compound 1 as a 2:1 (w/w) Compound 1/HPMCAS spray-dried dispersion. The capsule fill composition is presented in Table XVI.

Formulation F

- 25 Capsule (size#0) containing 200 mgA Compound 1 as a 2:1 (w/w) Compound1/HPMCAS spray-dried dispersion. The capsule fill composition is presented in Table XVI.

Dogs were dosed either after an overnight fast, or after a meal composed of 14g dry dog food, 8g olive oil, and 50 ml water. Blood (3ml) was collected from the jugular vein pre-dosing and at 0.17, 0.5, 1,2,4,7,10,24,32, and 48 hour post-dosing.

- 30 To 100 µl of a plasma sample, 5 ml methyl-tert-butyl ether (MTBE) and 1 ml 500 mM sodium carbonate buffer (pH9) were added, and the sample was vortexed for 1 min, then centrifuged for 5min. The aqueous portion of the sample was frozen in a dry ice/acetone bath and the MTBE layer was decanted and evaporated in a

vortex evaporator at 55°C. The sample was reconstituted with 75 µl of a mobile phase composed of 45% acetonitrile, 55% 50 mM NaH₂PO₄/30mM triethylamine (pH 3). Analysis was carried out by HPLC, using a Waters Nova-Pak C-18 column (3.9mmx150mm), with a C18/5u guard column, at a temperature of 26°C, at a flow rate of 1ml/min. Detection was by fluorescence (excitation wavelength 290nm; emission wavelength 348 nm).

Pharmacokinetic data are presented in Table XVII. C_{max} is the maximum observed plasma Compound1 concentration, averaged over the number of dogs dosed with each formulation. AUC_{0-∞} is the average area under the plasma

Compound 1 concentration vs. time curve.

These data demonstrate that spray-dried Compound1/HPMCAS dispersions, when orally dosed to beagle dogs, give a higher systemic Compound 1 exposure than after dosing an aqueous suspension of crystalline Compound 1.

Table XVI

Component	Formulation D	Formulation E	Formulation F
Compound 1/HPMCAS (1:1, w/w)	44%	--	--
Compound 1/HPMCAS (2:1, w/w)	--	60%	50%
Lactose, fast flow	22%	15%	10.8%
Microcrystalline Cellulose ¹	18.8%	15%	32.2%
Sodium Starch	8%	7%	5%

Glycolate ²			
Sodium lauryl Sulfate	2%	2%	1%
Magnesium Stearate	1%	1%	1%

¹ Avicel-102[®]

² Explotab[®]

Table XVII. Canine pharmacokinetics after oral dosing of Compound 1 formulations.

5 Canines were in fasted state, except where indicated.

Formula-tion	Dose ¹	n ²	C _{max} (uM)	AUC _{0-∞} (uMxhr/ml)	% Bioavail- ability ³
A	5mgA/kg	2	0.3	1.3	2.0
B	10mgA/kg	4	11.8	92.9	72.5
C	3.7mgA/kg	4	4.9	17.1	35.0
D	53.1 mgA	3	3.3	15.8	31.0
E	200 mgA	4	9.1	76.3	33.4
F	200 mg A	4	9.0	82.4	45.6
E(fed)	200 mg A	4	7.6	182.5	109.5

10 ¹ For comparison purposes, the average weight of beagle dogs used in this study was around 10 kg.

² Number of dogs studied

15 ³ Relative to a 10mgA/kg intravenous dose given to a separate group of dogs.

Example 34¹

This example demonstrates that dosing a spray dried dispersion of ziprasidone/HPMCAS to dogs results in a higher systemic ziprasidone exposure than

observed after dosing crystalline ziprasidone. Systemic exposure was measured as the area under the plasma ziprasidone concentration vs. time curve (AUC).

On two occasions, after an overnight fast, five beagle dogs were dosed with 20 mgA ziprasidone in either (a) a capsule containing a spray-dried 9:1 HPMCAS-
5 MF/Ziprasidone dispersion, or (b) a capsule containing a powder formulation of crystalline ziprasidone (30.2% ziprasidone hydrochloride, 58.6% hydrous lactose, 10% pregelatinized starch, 1.25% MgStearate). Following administration of the capsule, dogs were gavaged with 50 ml water. Water and food were withheld until 8 hr after dosing.

10 Pre-dosing, and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hr post-dosing, blood samples were taken, and plasma was harvested. Ziprasidone concentration was assayed using an HPLC assay. The mobile phase consisted of 40/60 aqueous NaH₂PO₄ (0.005M)/acetonitrile, and the column was a CN - Chromega column, 5 u, CN+NP, 25
15 cm x 4.6 mm (ES Industries). The flow rate was 1.5 ml/min, and detection was at 315 nm.

For the capsule containing crystalline ziprasidone, the observed average AUC(0-inf) was 561.6 ngxhr/ml. For the capsule containing the Ziprasidone/HPMCAS dispersion, the average AUC was 1056 ngxhr/ml.